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To assess the role of horses as amplification hosts during
the 1993 and 1996 Mexican Venezuelan equine encephalitis
(VEE) epizootics, we subcutaneously infected 10 horses by
using four different equine isolates. Most horses showed little
or no disease and low or nonexistent viremia. Neurologic dis-
ease developed in only 1 horse, and brain histopathologic
examination showed meningeal lymphocytic infiltration,
perivascular cuffing, and focal encephalitis. Three animals
showed mild meningoencephalitis without clinical disease. Viral
RNA was detected in the brain of several animals 12-14 days
after infection. These data suggest that the duration and scope
of the recent Mexican epizootics were limited by lack of equine
amplification characteristic of previous, more extensive VEE
outbreaks. The Mexican epizootics may have resulted from the
circulation of a more equine-neurotropic, subtype IE virus strain
or from increased transmission to horses due to amplification
by other vertebrate hosts or transmission by more competent
mosquito vectors.
enezuelan equine encephalitis virus (VEEV; Togaviridae:
Alphavirus) is an emerging pathogen of humans and
equines in many parts of the New World (1–3). Sporadic out-
breaks date to the 1930s or earlier in South America and have
affected hundreds of thousands of people, horses, donkeys,
and mules, causing high mortality rates in equines and severe
illness in humans. Most outbreaks have been confined to
northern South America, but one that began in Guatemala and
El Salvador in 1969 spread northward through Mexico and
reached Texas in 1971 (2,4,5). The etiologic agents during all
of the major VEE outbreaks were subtype IAB or IC VEEV.
Other subtypes of VEEV, including subtype IE strains that cir-
culate in sylvatic and swamp habitats of Central America and
Mexico, are traditionally considered enzootic, equine-aviru-
lent, and incapable of exploiting horses as amplification hosts
to cause widespread disease (6–9). 
Before 1993, the only VEE outbreak confirmed by virus
isolation in Mexico was the 1969–1971 epizootic/epidemic
(5). The etiologic agent was a subtype IAB VEEV strain that
likely originated from an inadequately inactivated equine vac-
cine preparation (10,11). Another VEE outbreak in Tamauli-
pas, Mexico, was detected serologically in 1965–1966, but no
virus strains were isolated (12,13). 
During 1993 and 1996, small outbreaks of equine encepha-
litis occurred near the Pacific Coast in the Mexican States of
Chiapas and Oaxaca, respectively. These outbreaks involved
125 and 32 equine cases, respectively, with case-fatality rates
of 50% and 38%; human VEE was not confirmed, although
human seroprevalence in the region is high (J.G.E.-F., S.C.W.,
unpub. data). Antigenic, sequencing and phylogenetic studies
indicated that the VEEV strains isolated from horses belong to
subtype IE and are closely related to enzootic strains isolated
nearby in sylvatic habitats on the Pacific Coast of Guatemala
from 1968–1980 (14–16). These Mexican outbreaks repre-
sented the first confirmed equine cases attributed to VEEV
subtype IE infection. Although the 1966 Tamaulipas epizootic
may have been caused by subtype IE viruses that circulate
nearby on the Gulf Coast of Mexico (12), the IE subtype was
not known to be equine virulent (8) and had never been shown
to be capable of equine amplification or of producing equine
epizootics. The 1993 and 1996 Mexican epizootics placed
these assumptions into doubt.
Partial sequence analysis of the PE2 envelope glycoprotein
precursor gene of four isolates made during the 1993 and 1996
Mexican outbreaks showed that they are strongly linked to
enzootic subtype IE VEEV isolates made in 1968 and 1980
along the Guatemalan Pacific Coast (14,15). Complete struc-
tural gene nucleotide sequence comparison of a Guatemalan
1968 isolate with a 1993 Mexican isolate showed that they dif-
fer by only 3% at the nucleotide level (14), and more recent
genomic sequencing of four strains has shown an overall
nucleotide sequence divergence of <2%. Only eight amino
acid changes are predicted to have accompanied the emer-
gence of the epizootic strains (16). This genetic similarity sug-
gests that small numbers of mutations in enzootic progenitors
may have resulted in acquisition of the equine-virulent pheno-
type, as indicated by previous studies of subtype IC VEEV
emergence in Venezuela (17).
To determine the virulence and viremia characteristics of
VEEV strains isolated during these Mexican outbreaks, and to
assess retrospectively the role of equines as amplification
hosts during epizootic transmission, we conducted experimen-
tal infections of horses with four different Mexican strains iso-
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lated from horses in 1993 and 1996. Although severe clinical
neurologic disease occurred in one animal, low levels of  vire-
mia or none was detected after subcutaneous inoculation  of
any of the horses, which suggests that equines were not the
principal amplification hosts in Mexico during the 1993 and
1996 epizootics.
Methods
Virus Preparation
The VEEV strains used for experimental infections are
described in Table 1. These viruses (without further passage)
were diluted in Eagle minimal essential medium (MEM) con-
taining antibiotics and 10% antibody-negative normal horse
serum before being used. 
Horse Infections
Ten antibody-negative horses were identified, ranging in
estimated age from 24 to 36 months. Only horses with no evi-
dence of preexisting alphavirus immunity were used in this
study of  experimental infections. One week before the VEEV
inoculations, all horses were treated with insecticide to elimi-
nate external parasites, and their temperature and blood counts
were recorded 3 days before the viral inoculations. The horses
were selected at random for inclusion in two experimental
groups of six and four animals, respectively.
Horses were inoculated with four different Mexican sub-
type IE VEE epizootic isolates (Table 1). Two strains were
obtained from the 1993 Chiapas outbreak and two others from
the 1996 Oaxaca outbreak. The first set of six horses was inoc-
ulated (three each) with strain CPA201, isolated from the brain
of an encephalitic horse during the 1993 Chiapas outbreak,
and strain OAX 131, isolated from the brain of a diseased
horse from the 1996 Oaxaca outbreak. The last group of four
horses (two each) was inoculated with OAX 142, isolated
from the brain of a moribund horse from Oaxaca in 1996, and
the I-290-93 strain, from the serum of a diseased horse from
the 1993 Chiapas outbreak.
All horses were infected by subcutaneous inoculation in
the shoulder region of 0.6–1.0 mL of MEM containing 10%
antibody-negative normal horse serum and 2,000 Vero cell
PFU of VEEV, a dose comparable to that inoculated by
alphavirus-infected mosquitoes (18). Although infection by
the bite of an infected mosquito may potentiate viremia lev-
els generated by some bunyaviruses (19,20), we used needle
inoculation for two reasons: 1) almost all past experimental
equine infections with other epizootic VEEV have been con-
ducted with needle infections, and we wanted to generate
data that could be compared directly to the literature;  and 2)
lack of a high containment insectary near the large animal
biocontainment facility precluded the use of infected mos-
quitoes.
Each pair or trio of horses inoculated with a given virus
strain was housed together in an isolation room within a large
animal biocontainment building. Each horse was placed in a
single stall and fed daily with fresh hay and water, and the
horse’s clinical signs were monitored at least twice daily. Rec-
tal temperature was recorded twice daily until day 14 postinoc-
ulation, beginning on the day before inoculation. Blood was
collected twice daily by venipuncture until day 9 and serum
samples were stored at -70°C for virus titration. Additional
blood was also collected into EDTA-containing tubes every
morning for up to 9 days, beginning the day before inocula-
tion, and analyzed for hematocrit, hemoglobin determination,
and platelet and leukocyte counts (also counts of basophils,
eosinophils, and monocytes).
The maintenance and care of animals complied with the
guidelines of the Centro Nacional de Investigaciones en
Microbiologia, Instituto Nacional de Investigaciones
Forestales, Agricolas y Pecuarias.
Histopathologic Studies
All of the horses, except one (no. 4) that died on day 12,
were killed 15 days after inoculation. Necropsies were carried
out to extract tissues of interest. For histopathologic studies,
samples were taken of white and gray matter from the anterior,
median, and posterior brain. The medula oblongata and a por-
tion of the spinal chord were taken at random. Tissue samples
<5 mm in thickness were fixed in 10% neutral buffered forma-
lin and processed by routine methods for paraffin embedding.
Sections were stained with hematoxylin and eosin.
Virus and Viral RNA Assays
Serum viremia levels were assayed by the inoculation of
serial dilutions onto monolayers of Vero cells to assess plaque
formation. Serial dilutions were also injected intracerebrally
into 1- to 2-day-old mice, and titers were calculated as 50%
lethal dose (LD50) values. Attempts to isolate VEEV from
brain samples included the inoculation of Vero cell monolay-
ers and inoculation of 1- to 2-day-old mice. 
Table 1. Mexican equine isolates of Venezuelan equine encephalitis virus used for experimental infections
Strain Date of isolation Place of isolation Tissue Passage historya
OAX131 25 June 1996 Chahuites, Oaxaca State Cerebrum sm1, RK1
CPA201 29 June 1993 Rancho El Recuerdo, Mapastepec, 
Chiapas State; 15°, 25′  N 93° 01′  W 
Brain sm1, RK1
OAX142 5 July 1996 Tapanatepec, Oaxaca State Cerebrum sm1, RK1
I-290-93 12 July 1993 Rancho La Guadalupe, Mapastepec, 
Chiapas State 15°, 25′  N 93° 00′  W
Serum sm1, RK1
aRK, rabbit kidney, sm;suckling mouse.Emerging Infectious Diseases  •  Vol. 9, No. 2, February 2003 163
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Reverse transcription–polymerase chain reactions (RT-
PCR) were also carried out on RNA extracted from paraffin-
embedded brain tissue from horses 1, 2, 3, 4, and 10 (insuffi-
cient brain tissue was left after histologic analyses on the
remaining horses) to detect VEEV RNA. RNA was extracted
from tissues by using the QIAGEN (Valencia, CA) RNeasy kit
according to the manufacturer’s protocol. Approximately 20
mg of each sample was placed in a microfuge tube with 1,200
µL of 100% xylene and vortexed to dissolve the paraffin. The
tissue was washed twice with an equal volume of 100% etha-
nol, then dried and resuspended in 350 µL of the QIAGEN
RTL buffer before being ground with a pestle and 0.5 mm zir-
conia/silica beads (BioSpec Products, Bartlesville, OK). The
RNA was eluted in 30 µL of Rnase-free water and 3 µL of
RNasin (Promega, Madison, WI) and used for RT-PCR.
RT-PCR was performed with the OneStep RT-PCR kit
(QIAGEN). The primers were designed to amplify genome
positions 8505–8882, yielding an expected 377-bp product:
sense primer: 5′ -CATAGACAATCCTGGTTACGACGAG-3′ ,
reverse primer: 5′ -CACCTGGCAAGCAGAAAGTATCC-3′ .
The 50-µL reaction mix was comprised of QIAGEN OneStep
RT-PCR buffer, 400 µM of each dNTP, 600 nM of each primer,
and 10 µL of RNA sample. The samples, along with negative
control (water alone) and positive control (viral RNA) samples,
were placed in a thermocycler for: 30 min at 50°C, 15 min at
95°C, followed by 40 cycles at 94°C for 1 min, 56°C for 1 min,
72°C for 1 min, and a final extension of 10 min at 72°C. A sem-
inested reaction followed with the same sense primer and a
nested reverse primer 5′ -GCACACCTGATGCACCTG-3′  to
amplify genome positions 8505–8642, for an expected 137-bp
product. For the seminested PCR, all initial PCR samples,
including the controls, were diluted 1/50. The seminested PCR
was performed by using Taq polymerase (Promega) for  30
cycles at 95°C for 30 sec, 56°C for 30 sec, 72°C for 2 min, and a
final 72°C extension for 10 min. 
PCR samples were analyzed on a 1% agarose gel, and visi-
ble DNA products were purified by using a QIAquick PCR
purification kit (QIAGEN) and sequenced by using the sense
primer and the ABI PRISM Big Dye Terminator v3.0 kit
(Applied Biosystems, Foster City, CA). Results were com-
pared to the genomic viral sequences for the Mexican viruses
used (GenBank Accession nos. AF448536, AF448537, and
AF448538).
Serologic Tests
Before the virus inoculation, serum samples from all
horses were tested for preexisting antibodies to VEE, eastern
(EEE), and western equine encephalitis (WEE) viruses by
using an enzyme-linked immunosorbent assay (ELISA) with
cell lysates prepared from BHK-21 cells infected with VEEV
strain Trinidad donkey (21,22), EEE virus strain 82V2137
(23), and WEE virus strain Fleming (24). After the horses
were injected, seroconversion was detected by using Vero cell
plaque reduction (>80%) neutralization tests (PRNT) with the
CPA201 strain.
Results
Clinical Signs and Symptoms
All animals became infected by VEEV as indicated by
seroconversion detected by PRNT (titers >1:40) on day 12 or
15 after inoculation. Symptoms of VEEV infection were
absent in the infected horses, and only clinical signs were
observed. In 9 of the 10 horses, the only clinical sign consis-
tent with VEE was intermittent fever. Horses nos.1–5 and 10
showed a moderate temperature elevation of approximately
1°–2°C, whereas horses 6–8 and 9 showed only a small eleva-
tion of approximately 0.5°–1.0°C.  Horse 6 did not display any
febrile response, only normal variation in its temperature
(Table 2). All animals had normal temperatures when they
were killed on day 12 or 15. When it occurred, fever peaked 2–
7 days after inoculation (Figure 1). Most horses displayed a
slight anorexia, but none completely ceased eating during the
study, except for horse no. 4 (described below). Diminished
Table 2. Outcome for horses experimentally infected with Venezuelan equine encephalitis virus strains
Horse no. Gender Virus strain
Maximum 
temperature (°C)
Maximum 
viremia levela Clinical outcome Histopathologic findings
1 Male OAX131 40.3 2.8 No disease Perivascular cuffing, minimal encephalitis
2 Male OAX131 40.2 1.4 No disease Perivascular cuffing, minimal encephalitis
3 Male OAX131 39.1 1.4 No disease Perivascular cuffing, minimal encephalitis
4 Male CPA201 40.8 2.4 Fatal encephalitis Perivascular cuffing, lymphocytic 
meningitis, focal encephalitis
5 Male CPA201 38.4 1.4 No disease Normal
6 Female CPA201 37.7 <0.6 No disease Normal
7 Male OAX142 38.2 <0.6 No disease Normal
8 Female OAX142 38.9 <0.6 No disease Normal
9 Male I-290–93 38.6 <0.6 No disease Normal
10 Male I-290–93 39.8 <0.6 No disease Normal
aTiters expressed as log10 suckling mouse intracerebral lethal dose50/mL serum.RESEARCH
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eating tended to coincide with fever, and appetence coincided
with a return to normal temperature.
Platelet counts increased slightly after day 5 in horses
infected with strain CPA201 (Figure 2). A modest leukopenia
occurred from day 2 to day 6 in two of three animals infected
with strain CPA201. Horse no. 4, infected with strain CPA201,
developed severe neurologic disease and showed the greatest
reduction in leukocyte counts (Figure 3). A slight leukocytosis
was seen in animals infected with OAX131 from day 3 to day
5. Otherwise, most animals showed little evidence of changes
in leukocyte counts. Hematocrit values did not drop (data not
shown) as in most previous studies of equines infected with
epizootic VEEV (6,9). Strains I-290–93 and OAX142 produced
no apparent reduction in platelet counts (data not shown).
Horse no. 4 was the only animal that exhibited clinical
signs of encephalitis. On day 6 postinoculation, this male
appeared weak, and on day 8 it exhibited nervousness, anor-
exia, pendular head movements, marked incoordination of the
extremities, penile relaxation, teeth grinding, muscular trem-
ors, restlessness, dyspnea, head shaking, excessive sweating,
movement of the ears in all directions, circular walking, and
blindness. On day 9 this animal was more tranquil, with less
sweating. It assumed an abnormal posture with its head resting
on the wall, and blindness was evident because the horse
began walking into various objects. On day 10, horse no. 4
showed incoordination, nervous ticks of the head, and com-
plete blindness. By day 11 a weight loss was evident; on day
12 the horse was prostrate and was therefore killed.
Viremia Levels
Of 10 horses infected with VEEV strains from the two
Mexican epizootics, none showed detectable viremia levels
when serum specimens were assayed for plaques on Vero
cells. When inoculation of newborn mice with serial dilutions
was used, two of three horses infected with strain CPA201 and
three horses infected with strain OAX131 demonstrated vire-
mia with low titers on days 1–3 and 2–4, respectively (Figure
4). The other two VEEV strains (I-290–93 and OAX142) did
not produce detectable viremia levels.
Virus Isolation and Viral RNA Detection
Virus could not be isolated from brain tissues of any of the
horses by inoculation of either Vero cells or baby mice. This
was not unexpected because the animals were killed 12–15
days after infection, when the virus was presumably cleared by
the immune response (neutralizing antibodies detected in all
animals). Of the brain samples from horses 1–4 and 10 which
were available for viral RNA detection by RT-PCR, all were
positive (Figure 5). Sequences of the PCR amplicons were all
identical to the parent strains, except for horse no. 4 infected
with strain CPA201, which had a thymine to cytosine synony-
mous transition at nucleotide position 8562. Strain I-290–93
used to infect horse 10 had not been sequenced previously, but
the sequence of the amplicon derived from horse 10 was iden-
tical to that of strain OAX131.
Necropsy and Histopathologic Findings
Gross pathologic lesions attributable to VEEV infection
were not observed upon necropsy in any of the horses. Sec-
Figure 1. Mean rectal temperatures of equines infected with four differ-
ent Mexican strains of subtype IE Venezuelan equine encephalitis virus.
Bars indicate standard deviations; shaded box indicates approximate
normal values.
Figure 2. Mean platelet counts in horses infected with virus strains
CPA201 and OAX131. Bars indicate standard deviations; shaded box
indicates approximate normal values. Normal temperature ranges from
The Merck Veterinary Manual, SE Ariello and A. Mays (eds.), 1998,
Merck & Company, Inc., Whitehouse Station, New Jersey.Emerging Infectious Diseases  •  Vol. 9, No. 2, February 2003 165
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tions of brain from all 10 horses were examined. The fatally
infected horse,  no. 4, showed multifocal perivascular cuffing,
lymphocytic meningitis, and focal encephalitis, characterized
by focal neuronal necrosis and neuronophagia with associated
microglial nodules (Figure 6B). Lesions were seen in gray and
white matter of the cerebrum and cerebellum, but were not
present in available sections of hippocampus or spinal cord.
Samples of skeletal muscle and kidney from horse no. 10
showed no pathologic changes. Lymphoid tissue was not
examined for any of the animals. All three horses infected with
isolate OAX131 also showed evidence of meningitis with
perivascular cuffing, and minimal encephalitis (Figure 6A).
Animal no. 2 displayed more intense lesions, with numerous
admixed eosinophils within leptomeningeal and perivascular
infiltrates (Figures 6C and 6D).
Discussion
Equine Amplification and VEE Emergence
Previously described experimental infections of equines
with epizootic subtype IAB and IC VEEV generally resulted
in high rates of overt disease with high-titered viremia levels,
often reaching 105-8 suckling mouse intracerebral lethal dose
50% units (SMICLD50/mL serum) (4,6,7,9,25–28). This high-
titered viremia, combined with the attractiveness of equines to
many potential mosquito vectors and poor anti-mosquito
defensive behavior, results in their high efficiency as amplifi-
cation hosts for epizootic virus transmission. Equine case-
fatality rates in these previous studies were generally approxi-
mately 50%, similar to those measured during natural epizoot-
ics. In contrast, enzootic VEEV belonging to subtypes ID
(6,9), IE (8,9), II (Everglades virus) (25), III (Mucambo virus),
and IV (Pixuna virus) (29) generally produces little or no clin-
ical illness and viremia less than 105 SMICLD50/mL serum
after experimental equine infection. These enzootic viruses,
including a subtype IE virus strain isolated near Veracruz near
the Gulf Coast of Mexico, also have not generally been associ-
ated with equine disease in nature (3,8). 
During 1969–1971, a VEE epizootic involving a subtype
IAB strain spread northward from Guatemala along the Pacific
Coast of Chiapas and Oaxaca States and then crossed into Ver-
acruz State on the Gulf Coast before moving north to Texas
(5). The reasons why the 1993 and 1996 Mexican outbreaks
did not spread northward along the same route are unknown,
but our studies suggest that the recent Mexican outbreaks were
fundamentally different than those caused by subtype IAB and
IC VEEV. The maximum viremia levels we measured in
experimentally infected horses were approximately 1,000-fold
lower than titers measured in previous studies using subtype
IAB and IC VEEV strains from more extensive outbreaks
(4,6,7,9,25–28,30). The titers we measured with the Mexican
equine strains were also much lower than the infection thresh-
olds for mosquitoes, as predicted by most experimental infec-
tions with VEEV (31–34). This finding indicates that equines
probably did not serve as amplification hosts to support epi-
zootic transmission cycles in Mexico during 1993 and 1996.
This lack of equine amplification, which is believed to be a
critical factor in VEE spread, probably limited the duration
and scope of the 1993 and 1996 Mexican epizootics. The low-
titered viremia level, even in the horse in which fatal encepha-
litis developed, also indicates that the Mexican subtype IE epi-
zootic viruses may be more neurotropic than other VEEV
strains that apparently reach the central nervous system only
after exceeding higher viremia titer thresholds (4,6,9). 
Other possible explanations for sudden appearance of
equine disease during the 1993 and 1996 outbreaks include
increased transmission to horses by efficient amplification in
other vertebrate hosts, or enhanced transmission by adaptation
of local VEEV strains to equiphilic mosquito vectors.
Although robust vector surveillance was not conducted during
the 1993 and 1996 Mexican epizootics, rainfall patterns and
Figure 3. Mean leukocyte counts in horses infected with virus strains
CPA201 and OAX131. Bars indicate standard deviations. Data for
horse no. 4, in whom severe neurologic disease developed after infec-
tion with strain CPA201, are shown individually. Bars indicate standard
deviations; shaded box indicates approximate normal values. Normal
temperature ranges from The Merck Veterinary Manual, SE Ariello and
A. Mays (eds.), 1998, Merck & Company, Inc., Whitehouse Station,
New Jersey.
Figure 4. Mean viremia titers in horses infected with four different Mexi-
can strains of subtype IE Venezuelan equine encephalitis virus. A log10
titer of 0.6 suckling mouse intracerebral lethal dose50 represents the
maximum sensitivity of the assay. Bars indicate standard deviations.RESEARCH
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anecdotal reports do not indicate unusually large mosquito
populations. Vector incrimination and susceptibility testing are
needed to assess the hypothesis that the Mexican epizootic
strains are more infectious for mosquitoes and more readily
transmitted than putative enzootic IE progenitors identified in
phylogenetic studies (15,16).
Equine Virulence of the Mexican VEEV Strains
In some respects, our results agreed with those of previous
experimental studies of VEEV in equines. Infection with the
Mexican VEEV strains resulted in mild leukopenia as has been
reported (9). However, the mild hematologic abnormalities
were more like those caused by enzootic VEEV strains than
epizootic, subtype IAB and IC variants (9). In contrast to many
VEE outbreaks attributed to subtype IAB and IC strains (3),
the four Mexican epizootic virus strains we tested in horses
produced an overall mortality rate of 10% but a case-fatality
rate of 100%. These results also contrast with the reported
case-fatality rates during the 1993 and 1996 Mexican out-
breaks of 50% and 37%, respectively, and with the 1993 attack
rate of 30% (14). The case-fatality rate differences probably
reflect sampling error because our experimental infections
produced disease in only one horse. Possible explanations for
the discrepancy in apparent:inapparent ratios in our study ver-
sus data collected during the outbreaks include an underreport-
ing of true inapparent infections during the 1993 epizootic, or
phenotypic differences between the virus populations we inoc-
ulated into horses versus those circulating naturally during the
epizootics. The latter possibility is discussed below.
Detection of VEEV RNA in the brain of five horses killed
12–14 days after infection, despite the absence of detectable
infectious virus, was somewhat surprising. This result indi-
cates that VEEV replicated in the brain of all horses, consis-
tent with some pathologic lesions in the asymptomatic animals
infected with strain OAX131 (Table 1). Persistence of viral
RNA in the brain after the disappearance of infectious virus
has also been reported for other alphaviruses (35).
Previous sequencing, rodent infection, and in vitro studies
with these Mexican VEEV strains suggested that mixed popu-
lations of viruses may circulate in nature, represented by dif-
ferences in amino acid composition and charge on the surface
of the E2 envelope spike glycoprotein (16). Genomic sequenc-
ing studies of the four Mexican VEEV strains we studied
revealed one amino acid difference: strain OAX142 has a Glu
residue at position 117 of the E2 envelope glycoprotein,
whereas the other three strains have Lys (16). The possibility
that the Lys residue does not represent the wild-type sequence
was considered previously because alphaviruses including
VEEV are known to accumulate artifactual, positive charge
amino acid changes in the E2 protein as the result of selection
for binding to heparan sulfate on the surface of cells in culture
(36). Because these changes reduce the virulence of alphavi-
ruses in laboratory rodents, they can place into question the
wild-type phenotype of VEEV strains.
However, our results further support the previous conclu-
sion that the E2-117 Lys residue was present in natural VEEV
isolates during the Mexican outbreaks as the consensus amino
acid, but possibly in a mixed quasispecies population (16). The
only strain that produced neurologic disease in our study was
CPA201, which has a consensus Lys at E2-117. Strain
OAX142, which has Glu-117, produced no detectable disease,
viremia, or hematologic alterations. These results are not con-
sistent with the hypothesis that the Lys at E2-117 resulted from
heparan sulfate adaptation during RK cell passage, which
would be expected to result in artificial attenuation (36).
Figure 5. Results on 1.5% agarose gel of reverse tranferase–poly-
merase chain reaction (RT-PCR) products stained with ethidium bro-
mide and imaged under UV light. M: 100-bp marker; H1–4, H10:
horses 1–4 and 10; (+): positive control viral RNA, 1.8 x 102 PFU
amplified; (N-): negative control for nested PCR (-); negative control
from single round RT-PCR. All horse samples and the positive control
show a band at the expected size (134 bp), and negative controls
show only the primers (below 100 bp).
Figure 6. Representative histopathologic changes of brains of infected
equines. A. Cerebrum, horse no. 3 (strain OAX131), showing perivas-
cular cuff of lymphocytes (original magnification x200, hematoxylin and
eosin [H&E] stain). B. Cerebrum, horse no. 4 (strain CPA201), showing
perivascular cuff of lymphocytes (original magnification x200, H&E
stain). C. Cerebral gray matter, horse no. 2 (strain OAX131), showing
infiltration of mononuclear cells into brain parenchyma (original magnifi-
cation x200, H&E stain), D. cerebral gray matter, horse no. 2, showing
numerous eosinophils within perivascular infiltrate (arrow) (original
magnification x200, H&E stain).Emerging Infectious Diseases  •  Vol. 9, No. 2, February 2003 167
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Because the Lys-117 mutation produces the small plaque phe-
notype characteristic of most epizootic, equine-virulent VEEV
strains, it remains a potential virulence determinant worthy of
further characterization by using cDNA clones and reverse
genetics.
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